These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25827099)

  • 21. Health technology assessment in Europe.
    Kristensen FB
    Scand J Public Health; 2009 Jun; 37(4):335-9. PubMed ID: 19493989
    [No Abstract]   [Full Text] [Related]  

  • 22. Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.
    Wu EQ; Zhou ZY; Xie J; Metallo C; Thokala P
    Pharmacoeconomics; 2019 Nov; 37(11):1349-1354. PubMed ID: 31591672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation guidelines in Latin America: a current snapshot.
    Augustovski F; Garay OU; Pichon-Riviere A; Rubinstein A; Caporale JE
    Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):525-37. PubMed ID: 20950069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment.
    Pharmacoeconomics; 2000 May; 17(5):443-4. PubMed ID: 10977386
    [No Abstract]   [Full Text] [Related]  

  • 25. [Health economics and HTA].
    Kulp W; Greiner W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):257-63. PubMed ID: 16465516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conditionally funded field evaluations and practical trial design within a health technology assessment framework.
    Bowen JM; Patterson LL; O'Reilly D; Hopkins RB; Blackhouse G; Burke N; Xie F; Tarride JE; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):324-31. PubMed ID: 19394573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Universal coverage with rising healthcare costs; health outcomes research value in decision-making in Latin America.
    Augustovski F; García Martí S; Pichon Riviere A; Rubinstein A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):657-9. PubMed ID: 22098279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity analysis for handling uncertainty in an economic evaluation.
    Limwattananon S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S59-64. PubMed ID: 24964700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spanish recommendations on economic evaluation of health technologies.
    López-Bastida J; Oliva J; Antoñanzas F; García-Altés A; Gisbert R; Mar J; Puig-Junoy J
    Eur J Health Econ; 2010 Oct; 11(5):513-20. PubMed ID: 20405159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The changing role of economic evaluation in valuing medical technologies.
    Rotter JS; Foerster D; Bridges JF
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):711-23. PubMed ID: 23252354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Using health state utility values in models exploring the cost-effectiveness of health technologies.
    Ara R; Wailoo A
    Value Health; 2012; 15(6):971-4. PubMed ID: 22999149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.
    Mantovani LG; Cortesi PA; Strazzabosco M
    Hepatology; 2016 Oct; 64(4):1331-42. PubMed ID: 26926906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How do cardiologists face health economics and health technology assessments?
    Boriani G
    Eur Heart J; 2012 Nov; 33(22):2757-8. PubMed ID: 23297423
    [No Abstract]   [Full Text] [Related]  

  • 34. A method for the early health technology assessment of novel biomarker measurement in primary prevention programs.
    Postmus D; de Graaf G; Hillege HL; Steyerberg EW; Buskens E
    Stat Med; 2012 Oct; 31(23):2733-44. PubMed ID: 22806952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Handling uncertainty of the economic evaluation result: sensitivity analysis.
    Limwattananon S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S59-65. PubMed ID: 19253488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies.
    Drummond M; Manca A; Sculpher M
    Int J Technol Assess Health Care; 2005; 21(2):165-71. PubMed ID: 15921055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relevance of cost-effectiveness analysis to clinicians and policy makers.
    Detsky AS; Laupacis A
    JAMA; 2007 Jul; 298(2):221-4. PubMed ID: 17622605
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
    Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
    Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A proposed guideline for economic evaluation of health technologies].
    López Bastida J; Oliva J; Antoñanzas F; García-Altés A; Gisbert R; Mar J; Puig-Junoy J
    Gac Sanit; 2010; 24(2):154-70. PubMed ID: 19959258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective.
    Forster M; Pertile P
    Health Econ; 2013 Dec; 22(12):1507-14. PubMed ID: 23225192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.